ADmit THERAPEUTICS - test for an early AD detection. Alzheimer's disease
test for an early AD detectionAlzheimer's disease
test for an early AD detectionAlzheimer's disease  

News

Oct. 23, 2020 ADmit Therapeutics receives a new Torres Quevedo Contract

The Torres Quevedo 2019 call from the Spanish Governent grants the contract of our bioinformatician Anna Guadall

 

 

Aug. 24, 2020 ADmit Therapeutics receives an important investment from the European Innovation Council

ADmit Therapeutics is a winner of the EIC Accelerator in its first application. It will receive up to €3.33M among grant and additional equity financing from EIC Fund. This support from the European Commission will allow the commercialization of the first early Alzheimer's diagnostic test in blood samples.




ADmit Therapeutics receives an important investment from the European Innovation Council
May 8, 2020 ADmit Therapeutics obtains the support of the Alzheimer’s Drug Discovery Foundation (ADDF) to develop its early Alzheimer’s diagnostic test

ADmit Therapeutics has received an investment of 497.652$ from the ADDF Diagnostics Accelerator for the development of its early Alzheimer’s disease diagnostic test in blood samples. The Diagnostics Accelerator is a research initiative that seeks to accelerate the development of affordable and accessible biomarkers to diagnose Alzheimer's disease and related dementias, and  advance the development of more targeted treatments. 

ADmit Therapeutics is a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL), located in Barcelona, which has been granted by Spanish and European grants, and has received private investments from Ship2B, GENESIS Biomed, BStartup10 and other investors since its inception at the end of 2017.




ADmit Therapeutics obtains the support of the Alzheimer’s Drug Discovery Foundation (ADDF) to develop its early Alzheimer’s diagnostic test
Apr. 2, 2020 ADmit Therapeutics has been certified as an Innovative SME



ADmit Therapeutics has been certified as an Innovative SME
Nov. 11, 2019 ADmit Therapeutics is supported with a Neotec grant

An important grant from the CDTI (Ministerio de Ciencia e Innovación) for our development plan along 2020.




ADmit Therapeutics is supported with a Neotec grant
Oct. 11, 2019 ADmit Therapeutics is granted by the EIT Health Digital Sandbox programme

This grant will allow us to get access to Scandinavian Biobanks




ADmit Therapeutics is granted by the EIT Health Digital Sandbox programme
Sept. 20, 2019 We have been granted with a Torres Quevedo Contract

Congratulations to our postdoc Marta Blanch!




We have been granted with a Torres Quevedo Contract
June 27, 2018 DemoDay at La Salle Technova

We present our project in the DemoDay in La Salle Technova, where Ship2B impulse with big corporates.

https://twitter.com...

June 20, 2018 Investment Forum from ACCIÓ 2018

Finalists in the Investment Forum from ACCIÓ 2018!

http://www.accio.gencat.cat...




Investment Forum from ACCIÓ 2018
May 15, 2018 MedTeX

ADmit Therapeutics selected in the MedTeX programme organized by Barcelona Scientific Park.

http://www.pcb.ub.edu...

Apr. 25, 2018 Lab4Health

ADmit Therapeutics is one of five start ups selected to participate in the Lab4Health in the social impact accelerator Ship2B.

https://www.ship2b.org...
https://twitter.com/Ship2B...
Dec. 21, 2017 ADmit Therapeutics S.L. is created

ADmit Therapeutics has been created, acquiring a license agreement with IDIBELL and University of Barcelona to develop a test for an early AD detection.

This website uses our own cookies and third-party cookies to collect information, in order to improve our services. Your continued use of this website constitutes acceptance of the installation of these cookies. The user has the option of configuring their browser in order to prevent cookies from being installed on their hard drive, although they must keep in mind that doing so may cause difficulties in their use of the webpage. I Agree  How to configure browser